A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours

摘要: It has been 30 years since the discovery of anti-tumour property paclitaxel (PTX), which successfully applied in clinic for treatment carcinomas lungs, breast and ovarian. However, PTX is poorly soluble water no targeting selectivity to tumour tissue. Recent advances active delivery vehicles have addressed some issues related lack solubility non-specific toxicities associated with PTX. These are designed specific cancer cells by addition ligands recognition receptors/antigens on cells. This article will focus various strategies serving as potential tools tissues, illustrating their use different models. review also highlights need further studies receptors organ binding efficiency these receptors.